2025/06/10 更新

写真a

ミズノ カズユキ
水野 和幸
MIZUNO Kazuyuki
所属
医学部附属病院 化学療法部 病院助教
職名
病院助教
外部リンク

学位 1

  1. 博士(医学) ( 2025年3月   名古屋大学 ) 

 

論文 45

  1. Author's reply: Letter to the editor: Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies.

    Suzuki T, Mizuno K, Ito T

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     2025年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.dld.2025.04.033

    PubMed

  2. Author's reply: Pancreatic injury in immune checkpoint inhibitor therapy: Clinical management challenges and considerations.

    Suzuki T, Mizuno K, Ito T

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     2025年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.dld.2025.04.035

    PubMed

  3. Steroid initiation dose and duration of steroid reduction for immune checkpoint inhibitor-induced liver injury

    Yamamoto, T; Ito, T; Suzuki, T; Mizuno, K; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Kawashima, H

    HEPATOLOGY RESEARCH     2025年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Hepatology Research  

    Aim: Treatment for severe immune checkpoint inhibitor (ICI)-induced liver injury (≥ Grade 3) requires prednisolone (PSL) administration and interruption of the underlying malignancy treatment. If the liver injury improves steadily, a lower initial dose of PSL is beneficial. We aimed to investigate the relationship between the initial dose of PSL and the response to PSL or the duration of PSL dose reduction. Methods: We retrospectively collected clinical data of patients treated with ICIs at Nagoya University Hospital between September 2014 and December 2023. Patients who received PSL for severe ICI-induced liver injury were divided according to the starting dose into group A (0.8 mg/kg/day) and group B (1.0 mg/kg/day). The time to improvement in liver injury and the reduction of the PSL dose to 10 mg/day were compared between the groups. Results: Overall, 1271 patients were treated with ICIs, of whom 80 experienced severe ICI-induced liver injury. Of the patients, 29 did not receive steroids, and five used PSL doses of <0.5 mg/kg/day. There were no significant differences in the baseline characteristics or laboratory data between the groups. The time to dose reduction to 10 mg/day PSL was significantly shorter in group A than in group B. The time to improvement in liver injury did not differ between the two groups. Conclusion: In some patients with severe ICI-induced liver injury, a dose of 0.8 mg/kg/day of PSL is sufficient to achieve a therapeutic effect and shorten the time required to reduce the dose to 10 mg/day.

    DOI: 10.1111/hepr.14200

    Web of Science

    Scopus

    PubMed

  4. Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast

    Takano, Y; Mizuno, K; Iwase, M; Morita, S; Torii, N; Kikumori, T; Ando, Y

    BREAST CANCER     2025年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Breast Cancer  

    Background: High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods: We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results: Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2− subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions: Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.

    DOI: 10.1007/s12282-025-01706-6

    Web of Science

    Scopus

    PubMed

  5. Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors

    Yasuda T., Ito T., Ishikawa T., Mizuno K., Yamamoto T., Yokoyama S., Yamamoto K., Imai N., Ishizu Y., Honda T., Koshiyama Y., Yasuda S., Toyoda H., Ando Y., Shimoyama Y., Kawashima H.

    Digestive and Liver Disease   57 巻 ( 4 ) 頁: 877 - 884   2025年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Digestive and Liver Disease  

    Background: Immune-related sclerosing cholangitis (irSC) induced by immune checkpoint inhibitors (ICIs) is relatively rare, and its clinical and pathological features are not well known. Aims: We aimed to compare the clinical course and pathological findings of irSC with those of non-irSC liver injury. Methods: Clinical data were retrospectively collected from 2416 patients with advanced malignancies treated with ICIs between September 2014 and October 2023. The data of patients with severe ICI-induced liver injury who underwent liver biopsy were analyzed and compared between patients with irSC and non-irSC. Results: Ninety-three (3.8 %) patients had severe ICI-induced liver injury, and 38 underwent liver biopsy. Of these, five were diagnosed with irSC. The irSC group had a significantly longer time to onset of ICI-induced liver injury and a lower rate of improvement of liver injury than did the non-irSC group (irSC, 3/5; non-irSC, 32/33). Liver biopsies revealed more moderate-to-severe pathological cholangitis in the irSC group than in the non-irSC group (irSC, n = 5/5; non-irSC, n = 16/33). Other pathological findings were similar between the two groups. Conclusion: Appropriate management of irSC requires an understanding of its characteristics of late onset and steroid resistance, and liver biopsy, in addition to imaging, may be useful for diagnosing irSC.

    DOI: 10.1016/j.dld.2025.01.037

    Scopus

    PubMed

▼全件表示

科研費 1

  1. 網羅的遺伝子解析によるirAE肝障害発症メカニズムの探索および治療アルゴリズムの開発

    研究課題/研究課題番号:23K07434  2023年4月 - 2026年3月

    科学研究費助成事業  基盤研究(C)

    水野 和幸

      詳細を見る

    担当区分:研究代表者 

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    がん治療において免疫チェックポイント阻害薬 (immune checkpoint inhibitor: ICI)の使用が増加している。ICIは従来の抗がん剤とは異なる副作用である免疫関連有害事象 (immune-related adverse event:irAE)を起こしうる。irAEによる肝障害に対しICI治療の中断と免疫抑制治療が必要となるが、無治療で改善する症例も存在し、ICIの再投与が施行可能なこともある。本研究はirAE肝障害の肝生検組織のRNAを調べ、irAE肝障害のメカニズムの探索、新規治療法の開発ならびにirAE肝障害の治療法や再投与の可否を予測するバイオマーカーを検索する。